The first closing of Xsensio’s new financing round with Swiss and international investors was CHF 4.2 million. The funds will flow into advancing the startup’s proprietory Lab-on-Skin sensing platform for continuous body monitoring through wearable devices.
Xsensio is a Lausanne based startup seeking to address the emerging field of wearable biosensing. It develops the unique Lab-on-Skin sensing platform to sense in real-time biochemical information at the skin’s surface and provide unprecedented real-time information about our health and wellness in a simple and minimally invasive way.
In May this year, the startup deployed its first Lab-on-Skin product in a pilot project at MotionLab. The aim was to monitor electrolytes in sweat to manage heat acclimation and dehydration of athletes, enabling better performance and reduced risk of injury in hot or humid environments such as the Olympic Games in Tokyo. Next year, the startup plans to introduce the platform to elite and professional athletes.
The investment round is led by Privilège Ventures, a Swiss venture capital firm with offices in Lugano, Zurich and Boston, and included the EIC Fund and other international investors. The proceeds will expand product and platform development, run clinical validation, and accelerate market launch through commercial partnerships in Europe and in the US.
Esmeralda Megally, co-founder and CEO of Xsensio: “The technology holds the potential for a paradigm shift in the way we deliver healthcare in the future, with a stronger focus on prevention through the use of minimally-invasive health monitoring devices. We are grateful to our company board and our current and new investors for believing in our vision. We look forward to working with Privilège Ventures in this new phase of growth”.
Jacqueline Ruedin Rüsch of Privilège Ventures: “We believe the opportunity for wearable biosensing is massive, and the team has the ambition and the talent to address this opportunity. I’m really excited to start this journey with Xsensio”.